Cellyan Biotechnology Co., Ltd (HKPD)
NASDAQ: HKPD · Real-Time Price · USD
0.1118
-0.0042 (-3.62%)
At close: Oct 1, 2026, 4:00 PM EDT
0.1106
-0.0012 (-1.07%)
After-hours: Oct 1, 2026, 5:57 PM EDT
Cellyan Biotechnology Revenue
In the fiscal year ending March 31, 2026, Cellyan Biotechnology had annual revenue of $13.43M, down -33.87%. Cellyan Biotechnology had revenue of $6.30M in the half year ending March 31, 2026, a decrease of -34.95%.
Revenue (ttm)
$13.43M
Revenue Growth
-33.87%
P/S Ratio
0.19
Revenue / Employee
$1,221,228
Employees
11
Market Cap
2.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.43M | -6.88M | -33.87% |
| Mar 31, 2025 | 20.31M | 3.63M | 21.72% |
| Mar 31, 2024 | 16.69M | 4.13M | 32.91% |
| Mar 31, 2023 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
HKPD News
- 2 months ago - Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period - GlobeNewsWire
- 3 months ago - Cellyan Biotechnology files $200M mixed securities shelf - TheFly
- 6 months ago - Cellyan Biotechnology Co. files to sell 12.5M Class A ordinary shares for holder - TheFly
- 8 months ago - Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - GlobeNewsWire
- 9 months ago - Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 10 months ago - DCS Announces Q3 2025 Quarterly Financial Statements - Newsfile Corp
- 1 year ago - Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024 - PRNewsWire
- 1 year ago - Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering - PRNewsWire